This update contains important information for community pharmacy teams.

CPNI ALERTS

DOH(NI) ALERTS

BSO ALERTS

Pharmacy team(s) can keep updated via CPNI’s Contractor Calendar and Contractor Emails.
Or report medicine shortages, pricing and staffing issues via CPNI’s Medicine Shortage Reporter and Situation Reporter.
Please bring this to the attention of your pharmacy team(s).

Kind regards

SENT ON BEHALF OF
Gerard Greene
Chief Executive
Dear Colleague
It has been confirmed that the 3rd concessionary price update below that was granted on 28th March 2024 will be the final update for the month.


There will be no further concessionary prices to announce for the month of March.
DrugPack
Size
Concessionary Price
Amoxicillin 250mg/5ml oral suspension100£2.49
Aripiprazole 5mg tablets28£5.64
Benzylpenicillin 600mg powder for solution for injection
vials
2£6.01
Betahistine 16mg tablets84£7.78
Calcipotriol 0.005% / Betamethasone dipropionate 0.05%
ointment
30£11.58
Cefalexin 500mg capsules21£2.50
Cefalexin 500mg tablets21£2.39
Chlorphenamine 2mg/5ml oral solution sugar free150£3.24
Cinacalcet 30mg tablets28£9.58
Clarithromycin 500mg tablets14£6.26
Clobazam 10mg tablets30£4.71
Co-amoxiclav 500mg/125mg tablets21£3.54
Co-careldopa 25mg/100mg tablets100£9.02
Co-codamol 30mg/500mg capsules100£5.63
Codeine 15mg/5ml linctus200£2.75
Dorzolamide 20mg/ml / Timolol 5mg/ml eye drops5£3.96
Duloxetine 30mg gastro-resistant capsules28£2.04
Estriol 1mg/g vaginal cream15£5.45
Etoricoxib 30mg tablets28£5.32
Famotidine 20mg tablets28£17.55
Famotidine 40mg tablets28£28.23
Glycopyrronium bromide 200micrograms/1ml solution for
injection ampoules
10£8.58
Hydrocortisone 1% cream15£2.36
Hydroxocobalamin 1mg/1ml solution for injection
ampoules
5£10.84
Ispaghula husk 3.5g effervescent granules sachets gluten
free sugar free
30£6.99
Ketoconazole 2% shampoo120£19.40
Lactulose 3.1-3.7g/5ml oral solution500£3.13
Latanoprost 50micrograms/ml / Timolol 5mg/ml eye drops2.5£7.48
Levothyroxine sodium 12.5microgram tablets28£17.57
Lofepramine 70mg tablets56£19.20
Mercaptopurine 50mg tablets25£8.62
Metoclopramide 10mg tablets28£1.09
Mometasone 0.1% cream30£3.88
Ondansetron 4mg tablets10£5.79
Pregabalin 300mg capsules56£3.08
Pregabalin 50mg capsules84£4.75
Prochlorperazine 3mg buccal tablets50£8.47
Promethazine hydrochloride 10mg tablets56£13.44
Propantheline bromide 15mg tablets112£100.61
Pyridostigmine bromide 60mg tablets200£19.33
Quetiapine 200mg tablets60£3.79
Quinine sulfate 200mg tablets28£7.65
Rasagiline 1mg tablets28£42.70
Rizatriptan 10mg tablets3£5.29
Sodium chloride 0.9% nebuliser liquid 2.5ml unit dose
ampoules
20£9.50
Sulpiride 200mg/5ml oral solution sugar free150£98.50
Tacrolimus 0.1% ointment30£15.59
Tacrolimus 0.1% ointment60£31.17
Tamsulosin 400microgram / Dutasteride 500microgram
capsules
30£14.83
Temazepam 10mg tablets28£24.75
Ursodeoxycholic acid 150mg tablets60£36.77
Zonisamide 100mg capsules56£20.28
Concessionary prices will be paid against the usual code, no additional endorsements are needed.
Please continue to notify CPNI of any pricing issues you are experiencing via our Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Contractor
Correspondence has been issued by SPPG 4th April 2024 regarding Community Pharmacy Adherence Support.

SUMMARY

  • Since 1st May 2023 the Drug Tariff has been changed so that instalment dispensing is an exception facility for use only where the prescriber considers it essential to prevent abuse or misuse.
  • As public funding is being utilised to support community pharmacies in meeting their obligations under the Disability Discrimination Act 1995 (DDA), SPPG are requesting information on the number of patients currently being provided with adherence support.
  • Adherence support includes provision of a Monitored Dosage System (MDS), pill crushers, reminder charts/alarms, or dexterity aids.
  • All patients receiving adherence support should be included with the following exceptions:
    • Patients who reside in Care Homes whose medicines are provided via MDS.
    • Patients with an instalment endorsement to prevent misuse or abuse of their medicines i.e. dispensing in skillets for daily or weekly patients. Please note: where these patients receive a form of adherence support such as MDS, they should be included on your list. There are instances where a patient receives both instalment dispensing and adherence support.
    • Patients who do not require support as a reasonable adjustment under DDA but for whom the pharmacy still provide adherence support e.g. requested for convenience.
  • The quarterly adherence return which was previously required will now be stood down.
  • SPPG have requested this information to be submitted by Friday 19th April 2024 using the following link.

ACTION

  • Contractors are asked to review the correspondence issued by SPPG 4th April 2024 regarding Community Pharmacy Adherence Support and share with relevant team members.
  • SPPG are requesting information on the number of patients currently being provided with adherence support using the following link by Friday 19th April 2024. Please note the exceptions listed in the correspondence.
  • The quarterly adherence return will now be stood down and is no longer required.
  • Guidance is available which provides information to community pharmacies in relation to their statutory requirements under DDA

For any further information please contact CPNI offices.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Contractor
Correspondence has been issued by SPPG 4th April 2024 regarding the Living Well Campaign.

SUMMARY

  • The survey for the campaign ‘Know you Units’ opened on the 1stApril 2024 and can be accessed here
  • The Living Well summary reports for the campaigns ‘Live Longer and Stronger’, ‘Care in the Sun’, ‘Childhood Immunisation’, ‘Keep Antibiotics Working’ are now available and can be accessed here.
  • The current campaign ‘Cancer Screening Saves Lives’ began on 1st April 2024 and NICPLD are hosting a bespoke training  webinar on 9th April to help pharmacy teams identify individuals who are eligible for cancer screening.

ACTION

  • Contractors are asked to review the correspondence issued by SPPG 4th April 2024 regarding the Living Well Service and share with relevant team members.
  • The survey for the campaign ‘Know Your Units’ is now available and must be completed before 6pm 29th April 2024.
  • NICPLD are hosting a webinar on 9th April 2024 to help pharmacy teams identify individuals who are eligible for cancer screening as part of the current campaign ‘Cancer Screening Saves Lives’

For any further information please contact CPNI offices.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive

Dear Colleague,

DoH(NI) has invited CPNI to nominate a Community Pharmacist, representative of Contractor members of CPNI, to join each of the new shadow Area Integrated Partnership Boards (AIPBs). These shadow AIPBs are being rolled out by the Department of Health across the five Trust geographical areas (Belfast, Southern, South-Eastern, Northern and Western areas) over the coming months as the next step in the implementation of a new Integrated Care System (ICS) for Northern Ireland.

ICS is the new Commissioning Framework for Northern Ireland. It is a single planning system that will help the health service to improve the health and well-being of the NI population and to address demand.

An AIPB is a planning partnership for the given geographical area with its over-arching aim being one of improving health and social care outcomes and reducing health inequalities for its local population.

The proposed membership of each shadow AIPB will include representation from across organisations and sectors who have a responsibility and/or interest in the health and social well-being of the population. The membership of each AIPB will therefore include representation from Community Pharmacy, Service Users and Carers, HSC Trusts, GP, local Councils and the Voluntary and Community Sectors. A test AIPB has been in operation in the Southern area since May 2023, with Mr. Sheelin McKeagney being the Community Pharmacy representative on the Southern area test AIPB.

This is a unique opportunity for Community Pharmacy representatives to play pivotal roles on these important new multi-sectoral AIPB structures within the ICS model that is being taken forward by the Health Minister Mr. Robin Swann MLA and the Permanent Secretary Mr. Peter May and led by Martina Moore, Director of the ICS NI Programme at DoH(NI). ICS and AIPBs are further evolutions of the Local Commissioning Group (LCG) and Integrated Care Partnership (ICP) bodies that were previously in place, of which many contractors and community pharmacists were members and played hugely important roles while serving on the LCGs or ICPs.

The letter requesting nominations from CPNI for the Community Pharmacy representative is available (here) with the Role Description for the Community Pharmacist Representative available (here) for your consideration and information.

Contractor Action:

You are asked to read the letter of request to CPNI and the Role Description document and to consider completing the Expressions of Interest form (here) if you, or one of your community pharmacy employee(s) or representatives would like to be considered for nomination as the Community Pharmacy AIPB representative in your Trust area.  Completed EoI forms should be returned to CPNI on, or before Tuesday 9th April 2024.

Please do not hesitate to contact me should you require any additional information.

Yours sincerely,

SENT ON BEHALF OF
GERARD GREENE
Chief Executive

Dear Contractor,

SPPG issued correspondence dated 29 March 2024 providing a further funding update for 2024/25.

SUMMARY

The opening global sum fees have been set from 1st April 2024:

 Fee rate April 2023Initial Opening Position
Ordinary Dispensing£1£1.07 per item
Instalment Dispensing£0.40£0.50 per item
Practice Allowance£20,900£24,000 per year

Work is ongoing with CPNI in relation to confirming additional funding streams for 2024/25 and it is anticipated we will be in a position to advise on these in the coming weeks.

ACTION

Read the attached correspondence and share with relevant members of your pharmacy team.

CPNI will keep you updated of any further developments.

Kind Regards,

SENT ON BEHALF OF
GERARD GREENE
Chief Executive